Explore more topics
News sentiment

ARS Pharmaceuticals, Inc. Common Stock (SPRY) news sentiment

How positive or negative ARS Pharmaceuticals, Inc. Common Stock's news headlines have been since Nov 30, 2020, week by week, with the last 90 sessions day by day and each recent headline's tone and source.

As of 2026-10-29

Average tone, last 30 sessions
-16From -100 (every headline negative) to +100 (every headline positive)
Headlines, last 30 sessions
73
Headlines, last 90 sessions
276
Change from the 90-session average
+7
Latest session
2026-10-29

Weekly headline tone since November 2020

Hover a week for its biggest stories; click to pin.

Tone8-week averageHeadlinesFiltered out (passing mentions)
Every week since Nov 30, 2020
SPRY headline tone: Every week since Nov 30, 2020, 192 weeks from November 30, 2020 to October 19, 2026.-100-75-50-25+25+50+75+1000Headlines202120222023202420252026

Coverage of ARS Pharmaceuticals, Inc. Common Stock over the last 30 trading sessions is negative (-16) across 73 headlines, 1 point below its one-year average of -15. The most widely carried story in the week of Oct 19, 2026 was "Contrasting ARS Pharmaceuticals (NASDAQ:SPRY) and Theravance Biopharma (NASDAQ:TBPH)", carried by 1 outlet.

Each point is one week of headlines about ARS Pharmaceuticals, Inc. Common Stock: the share of positive minus negative headlines, from -100 to +100, with the 8-week average drawn through it and the number of headlines beneath. Since coverage began, 713 headlines average -1.

Jump to a section

Tone mix

SPRY headlines by tone, last 52 weeks
positive
6%
neutral
71%
negative
23%

Week by week 51 weeks

Mar 17, 2025: 3 positive, 3 neutral, 0 negativeMar 24, 2025: 1 positive, 2 neutral, 2 negativeMar 31, 2025: 0 positive, 1 neutral, 0 negativeApr 7, 2025: 2 positive, 0 neutral, 0 negativeApr 21, 2025: 0 positive, 1 neutral, 0 negativeMay 12, 2025: 0 positive, 1 neutral, 0 negativeMay 19, 2025: 0 positive, 1 neutral, 0 negativeJun 2, 2025: 0 positive, 2 neutral, 0 negativeJul 28, 2025: 0 positive, 1 neutral, 0 negativeAug 11, 2025: 0 positive, 1 neutral, 0 negativeAug 18, 2025: 0 positive, 0 neutral, 1 negativeSep 1, 2025: 0 positive, 0 neutral, 1 negativeSep 15, 2025: 2 positive, 0 neutral, 0 negativeSep 22, 2025: 1 positive, 0 neutral, 1 negativeNov 3, 2025: 0 positive, 3 neutral, 0 negativeNov 10, 2025: 1 positive, 2 neutral, 1 negativeNov 17, 2025: 1 positive, 0 neutral, 1 negativeNov 24, 2025: 0 positive, 1 neutral, 0 negativeDec 22, 2025: 1 positive, 1 neutral, 0 negativeJan 5, 2026: 0 positive, 1 neutral, 0 negativeJan 12, 2026: 1 positive, 1 neutral, 0 negativeJan 19, 2026: 0 positive, 1 neutral, 0 negativeFeb 2, 2026: 1 positive, 1 neutral, 0 negativeFeb 16, 2026: 0 positive, 1 neutral, 0 negativeMar 9, 2026: 0 positive, 3 neutral, 0 negativeMar 23, 2026: 1 positive, 0 neutral, 0 negativeApr 6, 2026: 2 positive, 0 neutral, 0 negativeApr 13, 2026: 0 positive, 1 neutral, 0 negativeApr 20, 2026: 1 positive, 0 neutral, 0 negativeMay 11, 2026: 0 positive, 4 neutral, 0 negativeMay 18, 2026: 1 positive, 4 neutral, 1 negativeMay 25, 2026: 0 positive, 1 neutral, 0 negativeJun 1, 2026: 0 positive, 1 neutral, 0 negativeJun 15, 2026: 0 positive, 2 neutral, 0 negativeJun 22, 2026: 1 positive, 2 neutral, 2 negativeJun 29, 2026: 1 positive, 3 neutral, 3 negativeJul 6, 2026: 0 positive, 5 neutral, 0 negativeJul 13, 2026: 0 positive, 1 neutral, 0 negativeJul 20, 2026: 0 positive, 1 neutral, 0 negativeJul 27, 2026: 0 positive, 1 neutral, 0 negativeAug 3, 2026: 0 positive, 9 neutral, 1 negativeAug 10, 2026: 0 positive, 30 neutral, 10 negativeAug 17, 2026: 0 positive, 23 neutral, 10 negativeAug 24, 2026: 0 positive, 23 neutral, 8 negativeAug 31, 2026: 0 positive, 19 neutral, 6 negativeSep 7, 2026: 0 positive, 10 neutral, 10 negativeSep 14, 2026: 0 positive, 22 neutral, 7 negativeSep 21, 2026: 0 positive, 26 neutral, 8 negativeSep 28, 2026: 0 positive, 18 neutral, 3 negativeOct 5, 2026: 0 positive, 8 neutral, 3 negativeOct 19, 2026: 0 positive, 1 neutral, 0 negative
Mar 17, 2025Oct 19, 2026

Share of ARS Pharmaceuticals, Inc. Common Stock's 343 headlines over the last 52 weeks by the model's call, and the same mix week by week.

Biggest swings in the last year

The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.

Daily headline tone, last 90 sessions

Hover a session for its totals; click to pin.

Session tone8-session averageHeadlines
Last 57 sessions with a headline
SPRY average headline tone by session: Last 57 sessions with a headline, 57 sessions from June 25, 2026 to October 26, 2026.-100-75-50-25+25+50+75+1000HeadlinesJun 2026JulAugSepOct

Each point is the average score of the headlines about ARS Pharmaceuticals, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.

Tone by period

Show the table · 3 rows, 3 columns

Scroll sideways to compare all columns. Select a heading to sort.

Last 7 sessions20
Last 30 sessions73-16
Last 90 sessions276-23

Every headline in the period counts equally.

Headlines on Monday, October 26, 2026

1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.

Show the table · 1 row, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Financial Analysis: LENZ Therapeutics (NASDAQ:LENZ) & ARS Pharmaceuticals (NASDAQ:SPRY)www.tickerreport.com1Neutral

Headlines on Wednesday, October 21, 2026

1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.

Show the table · 1 row, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Contrasting ARS Pharmaceuticals (NASDAQ:SPRY) and Theravance Biopharma (NASDAQ:TBPH)www.dailypolitical.com1Neutral

Headlines on Tuesday, October 6, 2026

4 headlines, average tone 0: 0 positive, 4 neutral and 0 negative. Showing all 4.

Show the table · 4 rows, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Head-To-Head Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)www.dailypolitical.com1Neutral
Levi & Korsinsky Notifies ARS Pharmaceuticals, Inc. (SPRY) Shareholders ...www.pr-inside.com1Neutral
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Urged to Join Class ...www.pr-inside.com1Neutral
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Join Class Action Before ...www.pr-inside.com1Neutral

Headlines on Monday, October 5, 2026

7 headlines, average tone -36: 0 positive, 4 neutral and 3 negative. Showing all 7.

Show the table · 7 rows, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuitwww.prnewswire.com2Neutral
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY) - Contact ...www.pr-inside.com2Neutral
Securities Fraud Class Action Filed Against ARS Pharmaceuticals, Inc. ...www.pr-inside.com1Negative
Recover Investment Losses: Class Action Initiated Against ARS Pharmaceuticals, ...www.pr-inside.com1Negative
Class Action Lawsuit Filed: ARS Pharmaceuticals, Inc. (SPRY) - Join ...www.pr-inside.com1Negative
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Urged to Join Class ...www.pr-inside.com1Neutral
Investor Alert: Deadline Approaching to Join ARS Pharmaceuticals, Inc. ...www.pr-inside.com1Neutral

Headlines on Friday, October 2, 2026

3 headlines, average tone 0: 0 positive, 3 neutral and 0 negative. Showing all 3.

  • www.prnewswire.com · 1 outletINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesNeutral
  • www.pr-inside.com · 1 outletLost Money on ARS Pharmaceuticals, Inc. (SPRY)? Contact Levi & Korsinsky ...Neutral
  • www.prnewswire.com · 1 outletSPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Neutral
Show the table · 3 rows, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlineswww.prnewswire.com1Neutral
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Contact Levi & Korsinsky ...www.pr-inside.com1Neutral
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026www.prnewswire.com1Neutral

How the score works

A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.

  1. Which headlines count

    Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about ARS Pharmaceuticals, Inc. Common Stock, not a passing mention.

  2. How each headline is scored

    The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).

  3. When a headline counts

    Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.

  4. Repeated stories

    When several outlets carry the same headline, it counts once per session.